Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Stockholders??? Equity (Deficit)

v3.24.0.1
Consolidated Statements of Changes in Stockholders’ Equity (Deficit) - USD ($)
$ in Thousands
Total
Common Stock
Treasury Stock
Additional Paid-in Capital
Accumulated Deficit
Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2021   1,935,040        
Beginning balance (in shares) at Dec. 31, 2021     0      
Beginning balance at Dec. 31, 2021 $ 65,277 $ 0 $ 0 $ 264,954 $ (199,325) $ (352)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options, net of vesting of restricted shares (in shares)   914        
Exercise of stock options, net of vesting of restricted shares 28     28    
Release of restricted stock (in shares)   36,064        
Release of restricted stock 0          
Issuance of common stock under the 2018 employee stock purchase plan (in shares)   4,103        
Issuance of common stock under the 2018 employee stock purchase plan 214     214    
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. (in shares)   34,484        
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. 3,064     3,064    
Common Stock issued upon conversion of 2022 Promissory Note 0          
Sale of common stock, net of issuance costs (in shares)   52,469        
Sales of common stock, net of issuance costs 4,298     4,298    
Stock-based compensation expense 3,014     3,014    
Cumulative translation adjustment (120)         (120)
Net loss $ (50,894)       (50,894)  
Ending balance (in shares) at Dec. 31, 2022 2,063,074 2,063,074        
Ending balance (in shares) at Dec. 31, 2022 0   0      
Ending balance at Dec. 31, 2022 $ 24,881 $ 0 $ 0 275,572 (250,219) (472)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options, net of vesting of restricted shares (in shares)   1,895        
Exercise of stock options, net of vesting of restricted shares 58     58    
Release of restricted stock (in shares)   99,901        
Release of restricted stock 0          
Issuance of common stock under the 2018 employee stock purchase plan (in shares)   2,019        
Issuance of common stock under the 2018 employee stock purchase plan 48     48    
Issuance of common stock in lieu of cash bonus and consulting fees (in shares)   20,089        
Issuance of common stock in lieu of cash bonus and consulting fees $ 434     434    
Common Stock issued upon conversion of 2022 Promissory Note (in shares) 208,453 208,453        
Common Stock issued upon conversion of 2022 Promissory Note $ 1,800     1,800    
Sale of common stock, net of issuance costs (in shares)   1,466,147        
Sales of common stock, net of issuance costs 10,476     10,476    
Stock-based compensation expense 4,079     4,079    
Cumulative translation adjustment 54         54
Treasury stock repurchase (in shares)     (10,130)      
Treasury stock repurchase (502)   $ (502)      
Net loss $ (52,785)       (52,785)  
Ending balance (in shares) at Dec. 31, 2023 3,851,448 3,861,578        
Ending balance (in shares) at Dec. 31, 2023 (10,130)   (10,130)      
Ending balance at Dec. 31, 2023 $ (11,457) $ 0 $ (502) $ 292,467 $ (303,004) $ (418)